RCM
OREX

Reynolds Capital Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Reynolds Capital Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,360
Closed -$88K – 423
2014
Q1 		$88K Sell
1,360
-130
-9% -$8.79K 0.06% 372
2013
Q4 		$84K Sell
1,490
-390
-21% -$21.9K 0.05% 421
2013
Q3 		$115K Buy
1,880
+430
+30% +$29.1K 0.07% 387
2013
Q2 		$85K Buy
+1,450
New +$89.2K 0.06% 360

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Reynolds Capital Management's OREX Position: Q2 2014 in Review

Reynolds Capital Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2014, closing a stake of 1,360 shares — an estimated $88K sold.

Reynolds Capital Management first reported a position in OREX in Q2 2013 and held it in 4 quarters. The position peaked at $115K in Q3 2013. 129 funds tracked by Wall St. Rank hold OREX as of Q2 2014.

  • Reynolds Capital Management reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • Reynolds Capital Management sold 1,360 Orexigen Therapeutics, Inc. shares in Q2 2014, an estimated $88K.
  • Reynolds Capital Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 4 quarters.
  • Reynolds Capital Management's Orexigen Therapeutics, Inc. position peaked at $115K in Q3 2013.
  • 129 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2014.

Based on Reynolds Capital Management's 13F filing for Q2 2014, filed 8 Jul 2014.